Skip to main content
Top
Published in: BMC Pediatrics 1/2022

Open Access 01-12-2022 | Muscular Dystrophy | Case report

Beware of missed diagnosis in patients with multiple genetic diseases: a case report

Authors: Detong Guo, Xuemei Li, Nan Liu, Xiaoli Yu, Jianbo Shu, Wenchao Sheng, Dong Li, Chunquan Cai

Published in: BMC Pediatrics | Issue 1/2022

Login to get access

Abstract

Background

Duchenne muscular dystrophy (DMD) is an X-linked recessive inherited disorder caused by the absence of the Dystrophin protein. Cerebral cavernous malformations (CCMs) are the most common vascular abnormalities in the central nervous system caused by the absence of the products of the CCM genes. Most CCMs cases reported occurring in a sporadic form are often asymptomatic.

Case presentation

We report a rare case of a 7-year-old Chinese boy with a co-existing DMD and sporadic CCMs. We found classic clinical features of DMD and non-specific pathological changes in his brain. We made the definitive diagnosis based on the results of whole-exome sequencing (WES), a repeat from exon 3 to exon 9 of the DMD inherited from his mother, and a de novo heterozygote nonsense mutation C.418G > T of the PDCD10 exon 6.

Conclusion

We should take care to avoid missed diagnoses in patients with multiple genetic disorders.
Literature
1.
go back to reference Le Rumeur E. Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies. Bosn J Basic Med Sci. 2015;15:14–20.CrossRef Le Rumeur E. Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies. Bosn J Basic Med Sci. 2015;15:14–20.CrossRef
2.
go back to reference Wein N. Genetics and emerging treatments for Duchenne and Becker muscular dystrophy. Pediatr Clin North Am. 2015;62:723–42.CrossRef Wein N. Genetics and emerging treatments for Duchenne and Becker muscular dystrophy. Pediatr Clin North Am. 2015;62:723–42.CrossRef
3.
go back to reference Blat Y. Drug discovery of therapies for Duchenne Muscular Dystrophy. J Biomol Screen. 2015;20:1189–203.CrossRef Blat Y. Drug discovery of therapies for Duchenne Muscular Dystrophy. J Biomol Screen. 2015;20:1189–203.CrossRef
4.
go back to reference Allen DG. Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy. Physiol Rev. 2016;96:253–305.CrossRef Allen DG. Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy. Physiol Rev. 2016;96:253–305.CrossRef
5.
go back to reference Mouchtouris N. Management of cerebral cavernous malformations: from diagnosis to treatment. ScientificWorldJournal. 2015;2015:808314.CrossRef Mouchtouris N. Management of cerebral cavernous malformations: from diagnosis to treatment. ScientificWorldJournal. 2015;2015:808314.CrossRef
6.
go back to reference Morrison L. Cerebral cavernous malformation, familial. 1993. Morrison L. Cerebral cavernous malformation, familial. 1993.
7.
go back to reference Riant F. CCM molecular screening in a diagnosis context: novel unclassified variants leading to abnormal splicing and importance of large deletions. Neurogenetics. 2013;14:133–41.CrossRef Riant F. CCM molecular screening in a diagnosis context: novel unclassified variants leading to abnormal splicing and importance of large deletions. Neurogenetics. 2013;14:133–41.CrossRef
8.
go back to reference Riant F. Recent insights into cerebral cavernous malformations: the molecular genetics of CCM. FEBS J. 2010;277:1070–5.CrossRef Riant F. Recent insights into cerebral cavernous malformations: the molecular genetics of CCM. FEBS J. 2010;277:1070–5.CrossRef
9.
go back to reference Fischer A. Cerebral cavernous malformations: from CCM genes to endothelial cell homeostasis. Trends Mol Med. 2013;19:302–8.CrossRef Fischer A. Cerebral cavernous malformations: from CCM genes to endothelial cell homeostasis. Trends Mol Med. 2013;19:302–8.CrossRef
10.
go back to reference Guazzi P. Identification of the Kelch family protein Nd1-L as a novel molecular interactor of KRIT1. PLoS One. 2012;7:e44705.CrossRef Guazzi P. Identification of the Kelch family protein Nd1-L as a novel molecular interactor of KRIT1. PLoS One. 2012;7:e44705.CrossRef
11.
go back to reference Kuhlenbaumer G. Novel genomic techniques open new avenues in the analysis of monogenic disorders. Hum Mutat. 2011;32:144–51.CrossRef Kuhlenbaumer G. Novel genomic techniques open new avenues in the analysis of monogenic disorders. Hum Mutat. 2011;32:144–51.CrossRef
12.
go back to reference Srivastava S. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med. 2019;21:2413–21.CrossRef Srivastava S. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med. 2019;21:2413–21.CrossRef
13.
go back to reference Dalkilic I. Muscular dystrophies: genes to pathogenesis. Curr Opin Genet Dev. 2003;13:231–8.CrossRef Dalkilic I. Muscular dystrophies: genes to pathogenesis. Curr Opin Genet Dev. 2003;13:231–8.CrossRef
14.
go back to reference Sussman M. Duchenne muscular dystrophy. J Am Acad Orthop Surg. 2002;10:138–51.CrossRef Sussman M. Duchenne muscular dystrophy. J Am Acad Orthop Surg. 2002;10:138–51.CrossRef
15.
go back to reference Yang Y. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA. 2014;312:1870–9.CrossRef Yang Y. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA. 2014;312:1870–9.CrossRef
16.
go back to reference Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic causes of developmental disorders. Nature. 2015;519:223–8. Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic causes of developmental disorders. Nature. 2015;519:223–8.
17.
go back to reference Flemming KD. Cerebral cavernous malformation: what a practicing clinician should know. Mayo Clin Proc. 2020;95:2005–20.CrossRef Flemming KD. Cerebral cavernous malformation: what a practicing clinician should know. Mayo Clin Proc. 2020;95:2005–20.CrossRef
18.
go back to reference Wood CL. Short stature and pubertal delay in Duchenne muscular dystrophy. Arch Dis Child. 2016;101:101–6.CrossRef Wood CL. Short stature and pubertal delay in Duchenne muscular dystrophy. Arch Dis Child. 2016;101:101–6.CrossRef
19.
go back to reference Eiholzer U. Short stature: a common feature in Duchenne muscular dystrophy. Eur J Pediatr. 1988;147:602–5.CrossRef Eiholzer U. Short stature: a common feature in Duchenne muscular dystrophy. Eur J Pediatr. 1988;147:602–5.CrossRef
20.
go back to reference Call G. Failure to thrive in Duchenne muscular dystrophy. J Pediatr. 1985;106:939–41.CrossRef Call G. Failure to thrive in Duchenne muscular dystrophy. J Pediatr. 1985;106:939–41.CrossRef
21.
go back to reference Argente J. Genetic causes of proportionate short stature. Best Pract Res Clin Endocrinol Metab. 2018;32:499–522.CrossRef Argente J. Genetic causes of proportionate short stature. Best Pract Res Clin Endocrinol Metab. 2018;32:499–522.CrossRef
22.
go back to reference Liang Y. Challenges and opportunities for genetic diagnosis of children with short stature. Zhonghua Er Ke Za Zhi. 2020;58:443–6.PubMed Liang Y. Challenges and opportunities for genetic diagnosis of children with short stature. Zhonghua Er Ke Za Zhi. 2020;58:443–6.PubMed
Metadata
Title
Beware of missed diagnosis in patients with multiple genetic diseases: a case report
Authors
Detong Guo
Xuemei Li
Nan Liu
Xiaoli Yu
Jianbo Shu
Wenchao Sheng
Dong Li
Chunquan Cai
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Pediatrics / Issue 1/2022
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-022-03490-0

Other articles of this Issue 1/2022

BMC Pediatrics 1/2022 Go to the issue